Cargando…

Potential contribution of haemoconcentration to changes in lipid variables with empagliflozin in patients with type 2 diabetes: A post hoc analysis of pooled data from four phase 3 randomized clinical trials

AIM: To examine the association between changes in lipids and markers of haemoconcentration (haematocrit and serum albumin) with empagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, in patients with type 2 diabetes (T2D) using pooled data from four phase 3 randomized trials. MATERIALS AND MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lund, Søren S., Sattar, Naveed, Salsali, Afshin, Neubacher, Dietmar, Ginsberg, Henry N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290508/ https://www.ncbi.nlm.nih.gov/pubmed/34463415 http://dx.doi.org/10.1111/dom.14534

Ejemplares similares

Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study
por: Nishimura, Rimei, et al.
Publicado: (2015)

Development of a diagnostic sensor for measuring blood cell concentrations during haemoconcentration
por: Robertson, Craig A., et al.
Publicado: (2016)

Relative blood volume changes during haemodialysis estimated from haemoconcentration markers
por: Pstras, L., et al.
Publicado: (2020)

Clinical implications of the blood urea nitrogen/creatinine ratio in heart failure and their association with haemoconcentration
por: Sujino, Yasumori, et al.
Publicado: (2019)

Abstract 25: Glycemic variability of oral semaglutide versus empagliflozin: A post hoc analysis of PIONEER 2
por: Shabeer, D, et al.
Publicado: (2022)

Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR‐Reduced
por: Ferreira, João Pedro, et al.
Publicado: (2022)

Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial
por: Biegus, Jan, et al.
Publicado: (2022)

Rationale and design of the EMPERIAL‐Preserved and EMPERIAL‐Reduced trials of empagliflozin in patients with chronic heart failure
por: Abraham, William T., et al.
Publicado: (2019)

Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial
por: Fitchett, David, et al.
Publicado: (2021)

Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled( )
por: Ferreira, João Pedro, et al.
Publicado: (2022)

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(®) trial
por: Fitchett, David, et al.
Publicado: (2016)

Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial
por: Voors, Adriaan A., et al.
Publicado: (2022)

Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus
por: Kinduryte Schorling, Ona, et al.
Publicado: (2020)

Corrigendum to: Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled
Publicado: (2022)

Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial( )
por: Doehner, Wolfram, et al.
Publicado: (2022)

Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events
por: Rosenstock, Julio, et al.
Publicado: (2015)

Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial
por: Ferreira, João Pedro, et al.
Publicado: (2020)

Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial
por: Verma, Subodh, et al.
Publicado: (2021)

Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA‐REG OUTCOME trial
por: Ferreira, João Pedro, et al.
Publicado: (2021)

Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta‐analysis of data from randomized placebo‐controlled trials
por: Salsali, A., et al.
Publicado: (2016)

Low‐dose empagliflozin as adjunct‐to‐insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy
por: Perkins, Bruce A., et al.
Publicado: (2020)

Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial
por: Roden, Michael, et al.
Publicado: (2015)

Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies
por: Ginsberg, Henry N., et al.
Publicado: (2018)

Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial
por: Sattar, Naveed, et al.
Publicado: (2018)

Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme
por: Zannad, Faiez, et al.
Publicado: (2022)

Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs
por: Liu-Seifert, Hong, et al.
Publicado: (2005)

Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure: A Secondary Analysis of EMPEROR-Pooled
por: Ferreira, João Pedro, et al.
Publicado: (2022)

The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis
por: Nasrallah, Henry A., et al.
Publicado: (2017)

New insights into the role of empagliflozin on diabetic renal tubular lipid accumulation
por: Sun, Hong, et al.
Publicado: (2022)

MON-645 Association of Baseline Cardio-Metabolic Parameters on the Treatment Effects of Empagliflozin When Added to Metformin in Patients with T2D
por: Inzucchi, Silvio E, et al.
Publicado: (2020)

Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial
por: Kosiborod, Mikhail N., et al.
Publicado: (2022)

Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials
por: Henry, Robert R., et al.
Publicado: (2018)

Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I–III Clinical Trials
por: Kohler, Sven, et al.
Publicado: (2017)

Management of Lipid Abnormalities in Patients with Diabetes
por: Sillars, Anne, et al.
Publicado: (2019)

Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction – a post-hoc analysis of the EMMY trial
por: Benedikt, Martin, et al.
Publicado: (2023)

Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity
por: Liu, Yihai, et al.
Publicado: (2021)

Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control
por: Ray, Kausik K., et al.
Publicado: (2016)

Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus
por: Neeland, Ian J, et al.
Publicado: (2016)

Design of a prospective patient‐level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure
por: Packer, Milton, et al.
Publicado: (2020)

Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials
por: Tuttle, Katherine R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mkc5cggeahgsge3tlp5578kb72